Entera Bio’s (ENTX) “Buy” Rating Reiterated at HC Wainwright

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 411.51% from the company’s current price.

Entera Bio Price Performance

NASDAQ:ENTX traded up $0.01 during mid-day trading on Tuesday, hitting $1.96. The company’s stock had a trading volume of 9,763 shares, compared to its average volume of 120,608. Entera Bio has a 1 year low of $1.30 and a 1 year high of $3.35. The stock has a market cap of $69.96 million, a price-to-earnings ratio of -7.52 and a beta of 1.62. The business’s fifty day moving average is $2.23 and its two-hundred day moving average is $2.02.

Institutional Investors Weigh In On Entera Bio

Hedge funds have recently modified their holdings of the company. Perigon Wealth Management LLC purchased a new stake in shares of Entera Bio during the 4th quarter worth about $325,000. Northern Trust Corp purchased a new stake in shares of Entera Bio during the 4th quarter worth about $450,000. Parkman Healthcare Partners LLC boosted its stake in shares of Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after acquiring an additional 9,558 shares in the last quarter. Finally, Knoll Capital Management LLC boosted its stake in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after acquiring an additional 2,000,000 shares in the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.